SCHEMBL6789082

SCHEMBL6789082

COc1cc2nccc(Nc3cc(NC(=O)c4cccc(N(C)C)c4)ccc3C)c2cc1OC

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 20/20 0.77
▸ EGFR P00533 3/20 0.63
▸ SMO Q99835 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ RAF1 P04049 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ BRAF P15056 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ MAPK11 Q15759 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6788172 0.85 MAPK14 (0.59) MAPK14EGFRALDH1A1MAPT
SCHEMBL13198193 0.80 MAPK14 (0.61) MAPK14SMOKDM4EALDH1A1RAF1
SCHEMBL6782336 0.79 MAPK14 (1.00) MAPK14SMOKDM4EALDH1A1RAF1
SCHEMBL6781511 0.79 MAPK14 (1.00) MAPK14SMOKDM4EALDH1A1RAF1
SCHEMBL2747824 0.79 MET (0.62) MAPK14EGFRCYP3A4BRAF
SCHEMBL6792822 0.78 MAPK14 (0.78) MAPK14EGFRKDM4EALDH1A1RAF1
Hydrochloric Acid SCHEMBL6789866 0.78 EGFR (0.64) MAPK14EGFRALDH1A1
SCHEMBL4548864 0.78 MET (0.60) MAPK14EGFRCYP3A4BRAF
SCHEMBL5007830 0.77 MAPK14 (0.72) MAPK14SMOKDM4EALDH1A1RAF1
SCHEMBL6477643 0.76 MAPK14 (0.85) MAPK14SMOKDM4EALDH1A1RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716847-B2 ANTIALLERGENS, ANTIINFLAMMATORY ASTRAZENECA AB (SE) 2004-04-06 — — US disclosed
US-6593333-B1 Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various ASTRAZENECA AB (SE) 2003-07-15 — — US disclosed
EP-1117653-B1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-02-05 — — EP disclosed
EP-1117653-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2001-07-25 — — EP disclosed
WO-2000020402-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2000-04-13 — — WO disclosed
Send feedback